絞り込み

17368

広告

Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.

著者 Heslegrave A , Heywood W , Paterson R , Magdalinou N , Svensson J , Johansson P , Öhrfelt A , Blennow K , Hardy J , Schott J , Mills K , Zetterberg H
Mol Neurodegener.2016 ; 11(1):3.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (7view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

Research Materials

The discovery that heterozygous missense mutations in the gene encoding triggering receptor expressed on myeloid cells 2 (TREM2) are risk factors for Alzheimer's disease (AD), with only the apolipoprotein E (APOE) ε4 gene allele conferring a higher risk, has led to increased interest in immune biology in the brain. TREM2 is expressed on microglia, the resident immune cells of the brain and has been linked to phagocytotic clearance of amyloid β (Aβ) plaques. Soluble TREM2 (sTREM2) has previously been measured in cerebrospinal fluid (CSF) by ELISA but in our hands commercial kits have proved unreliable, suggesting that other methods may be required. We developed a mass spectrometry method using selected reaction monitoring for the presence of a TREM2 peptide, which can be used to quantify levels of sTREM2 in CSF.
PMID: 26754172 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード